COMP <GO>
STE vs JNJ // ALTMAN Z-SCORE & DEBT/EQUITY
STERIS plc (Ireland) (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: STE 5
— JNJ 8
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: JNJ
LAST: $227.12 (-2.16%) • MKT CAP: $22.63B
balance-sheet
5.40
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
balance-sheet
5.59
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (STE VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | STE | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 44.20% | 67.90% | -23.70 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 10.10% | 25.50% | -15.40 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 17.0x | 18.5x | -1.50 | STE | /valuation <GO> |
| Free Cash Flow Yield | 4.30% | 2.97% | +1.33 | STE | /fcf-yield <GO> |
| Operating Margin | 18.60% | 34.70% | -16.10 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 13.20% | 28.50% | -15.30 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 8.70% | 6.00% | +2.70 | STE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.07% | 0.00% | +1.07 | STE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 5.40 | 5.59 | -0.19 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | STE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 7.20% | 0.00 | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.9 | 60.4 | -3.45 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 1.08 | 0.00 | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 26.9x | 23.0x | +3.90 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $22.63B | $662.49B | -$639.86B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | STE REV | JNJ REV | STE GROSS % | JNJ GROSS % | STE FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $5.94B | $94.19B | 44.2% | 67.9% | $972.4M | $19.70B |
| FY 2024 | $5.46B | $88.82B | 44.0% | 69.1% | $778.0M | $19.84B |
| FY 2023 | $5.14B | $85.16B | 44.0% | 44.0% | $742.1M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
STE // BETA 1.08
JNJ // BETA 1.08